中信建投：中国医药企业积极探索多元化出海重点把握新增量及行业并购整合

智通财经2025-11-20

智通财经APP获悉，中信建投发布研报称，中国医药产业迈入“创新兑现+全球布局”的关键阶段，人口与内需基数、全产业链制造能力构成核心支撑，企业积极探索多元化的出海路径。面对全球竞争与政策深化，行业需“立足于内、创新引领、开拓于外”，对内强化供应链安全与合规能力，对外深化多元化出海布局。展望2026年，重点把握创新商业化、全球化突破、政策优化带来的新增量及行业并购整合的机遇。中信建投主要观点如下：全球...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2584390459?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-20 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584390459","market":"hk","top_or_hot":-1,"title":"中信建投：中国医药企业积极探索多元化出海 重点把握新增量及行业并购整合","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，中信建投发布研报称，中国医药产业迈入“创新兑现+全球布局”的关键阶段，人口与内需基数、全产业链制造能力构成核心支撑，企业积极探索多元化的出海路径。面对全球竞争与政策深化，行业需“立足于内、创新引领、开拓于外”，对内强化供应链安全与合规能力，对外深化多元化出海布局。展望2026年，重点把握创新商业化、全球化突破、政策优化带来的新增量及行业并购整合的机遇。中信建投主要观点如下：全球...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1371438.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中信建投：中国医药企业积极探索多元化出海 重点把握新增量及行业并购整合</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中信建投：中国医药企业积极探索多元化出海 重点把握新增量及行业并购整合\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-20 11:50 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1371438.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中信建投发布研报称，中国医药产业迈入“创新兑现+全球布局”的关键阶段，人口与内需基数、全产业链制造能力构成核心支撑，企业积极探索多元化的出海路径。面对全球竞争与政策深化，行业需“立足于内、创新引领、开拓于外”，对内强化供应链安全与合规能力，对外深化多元化出海布局。展望2026年，重点把握创新商业化、全球化突破、政策优化带来的新增量及行业并购整合的机遇。中信建投主要观点如下：全球...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1371438.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600056","symbol_name":"中国医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1371438.html","article_id":"2584390459","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584390459","pubTimestamp":1763610615,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，中信建投发布研报称，中国医药产业迈入“创新兑现+全球布局”的关键阶段，人口与内需基数、全产业链制造能力构成核心支撑，企业积极探索多元化的出海路径。中信建投主要观点如下：全球视角：创新价值凸显，中国力量加速渗透中国医药具“创新升级+供应链韧性”优势，2025前三季度创新药海外授权超去年全年，器械也在积极探索出海路径。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600056":"中国医药","601066":"中信建投","BK0188":"融资融券","BK0175":"白马股","BK0250":"批发","BK0082":"国资改革","BK0010":"央企","BK0028":"国家队","BK0276":"资本市场","BK0185":"二线龙头"},"translate_title":"CITIC Construction Investment: Chinese pharmaceutical companies actively explore diversified overseas expansion and focus on grasping new increments and industry mergers and acquisitions","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600056":1.5,"601066":1.5},"content_text":"智通财经APP获悉，中信建投发布研报称，中国医药产业迈入“创新兑现+全球布局”的关键阶段，人口与内需基数、全产业链制造能力构成核心支撑，企业积极探索多元化的出海路径。面对全球竞争与政策深化，行业需“立足于内、创新引领、开拓于外”，对内强化供应链安全与合规能力，对外深化多元化出海布局。展望2026年，重点把握创新商业化、全球化突破、政策优化带来的新增量及行业并购整合的机遇。中信建投主要观点如下：全球视角：创新价值凸显，中国力量加速渗透中国医药具“创新升级+供应链韧性”优势，2025前三季度创新药海外授权超去年全年，器械也在积极探索出海路径。美国主导早期研发与高端定价，但跨国药企专利悬崖下需求旺盛，中国资产全球性价比凸显，内外协同空间广阔。国内的价值重塑：聚焦高质量发展，筑牢创新与合规根基①政策：聚焦高质量发展，集采优化、多元化支付、医疗服务价改推进;②制药链：创新药进入商业化放量期，关注供应链安全;③器械：国产替代向中高端延伸，看好出海、新科技(AI、脑机接口)及并购整合等新技术落地;④跟踪中药、药店、医疗服务等行业触底回升与转型升级的机会。出海的价值重塑：多维突破，构建全球化新格局①创新药：BD常态化，迈入国际化2.0时代;②产业链：国内和海外需求回暖;③原料药：化解短期扰动，向特色原料药/ CDMO转型;④器械：开拓海外市场，创新器械自主销售与BD并行;⑤血制品/疫苗：静丙海外注册、疫苗出海模式多元。2026年投资展望：价值重塑，静待花开①创新主线：创新药(ADC、二代IO、小核酸、减重)、创新器械(AI医疗、脑机接口等)。②出海主线：具备全球临床数据与国际化能力的创新药企、积极开拓海外市场的器械公司。③边际变化主线：1)政策红利：医疗设备更新等;2)供求改善：CXO行业订单复苏、上游物料国产替代及海外销售。④整合主线：器械细分赛道龙头、中药国企改革标的、具备产业链整合能力的制药企业。风险提示：药械招采及控费政策严于预期、行业竞争激烈程度强于预期、创新药及器械审批进度不及预期，外部环境变化难以判断。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584390459","isCrawlerRequest":true}

中信建投：中国医药企业积极探索多元化出海 重点把握新增量及行业并购整合

精彩评论

中信建投：中国医药企业积极探索多元化出海重点把握新增量及行业并购整合